ARTICLE
17 November 2023

Danco Laboratories And The Department Of Justice File Briefs As Battle Over Abortion Drug Continues In U.S. Supreme Court

SG
Shipman & Goodwin LLP
Contributor
Shipman & Goodwin LLP  logo
Shipman & Goodwin’s value lies in our commitment -- to our clients, to the profession and to the community. We have one goal: to help our clients achieve their goals. How we accomplish it is simple: we devote our considerable experience and depth of knowledge to understand each client’s unique needs, business and industry, and then we develop solutions to meet those needs. Clients turn to us when they need a trusted advisor. With our invaluable awareness of each client’s challenges, we can counsel them at every step -- to keep their operations running smoothly, help them navigate complex business transactions, position them for future growth, or resolve business disputes. The success of our clients is of primary importance to us and our attorneys invest meaningful time getting to know the client's business and are skilled in the practice areas and industry sectors critical to that success. With more than 175 attorneys in offices throughout Connecticut, New York and in Washington, DC, we serve the needs of
On November 7, 2023, the Department of Justice ("DOJ") and Danco Laboratories ("Danco"), the distributor of mifepristone, filed briefs in opposition to Alliance for Hippocratic Medicine's ("Alliance")...
United States Food, Drugs, Healthcare, Life Sciences
To print this article, all you need is to be registered or login on Mondaq.com.

On November 7, 2023, the Department of Justice ("DOJ") and Danco Laboratories ("Danco"), the distributor of mifepristone, filed briefs in opposition to Alliance for Hippocratic Medicine's ("Alliance") Conditional Cross-Petition for a Writ of Certiorari requesting that the U.S. Supreme Court dismiss a challenge brought forth by Alliance. See, https://www.shipmangoodwin.com/insights/abortion-opponents-seek-full-supreme-court-review-of-fifth-circuit-holding.html.

Alliance, in its legal argument sought to invoke a legal doctrine known as the "reopening" doctrine to circumvent the statute of limitations issue which initially rendered their challenge untimely. This doctrine allows for an otherwise untimely challenge to proceed if the agency reconsiders its former decision. Alliance asserted that the Federal Drug Administration's ("FDA") actions in 2016 and 2021 effectively reopened the 2000 approval of Mifeprex, thereby resetting the statute of limitations. However, the Fifth Circuit rejected this argument, concluding that the reopening doctrine did not apply.

The DOJ and Danco argue that Alliance's challenge to the 2000 approval was untimely, and have requested that the U.S. Supreme Court dismiss the challenge. Specifically, in its brief, Danco contends that Alliance's request does not align with legal precedent and addresses a question that "no court has addressed." See, Danco's Brief in Opposition, page 20. Moreover, Danco maintains that even if the reopening doctrine is valid, it does not apply to the FDA's actions concerning Mifeprex. Id. at page 14. The arguments presented by the DOJ and Danco emphasize that neither express nor constructive "reopening" amount to a substantive reconsideration of the 2000 approval. Id. at page 16.

As it stands, the U.S. Supreme Court's decision to take up or reject this case will be a pivotal moment in the ongoing debate over reproductive rights and drug regulation.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

ARTICLE
17 November 2023

Danco Laboratories And The Department Of Justice File Briefs As Battle Over Abortion Drug Continues In U.S. Supreme Court

United States Food, Drugs, Healthcare, Life Sciences
Contributor
Shipman & Goodwin LLP  logo
Shipman & Goodwin’s value lies in our commitment -- to our clients, to the profession and to the community. We have one goal: to help our clients achieve their goals. How we accomplish it is simple: we devote our considerable experience and depth of knowledge to understand each client’s unique needs, business and industry, and then we develop solutions to meet those needs. Clients turn to us when they need a trusted advisor. With our invaluable awareness of each client’s challenges, we can counsel them at every step -- to keep their operations running smoothly, help them navigate complex business transactions, position them for future growth, or resolve business disputes. The success of our clients is of primary importance to us and our attorneys invest meaningful time getting to know the client's business and are skilled in the practice areas and industry sectors critical to that success. With more than 175 attorneys in offices throughout Connecticut, New York and in Washington, DC, we serve the needs of
See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More